RxDoctor Payments Data

Bethany Thomas

Family · Philadelphia, PANPI 1104242825

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $91,949 of the $126,258 with a category attached, or 72.8%. 5 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 39.2% of the total. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$126,258in general payments, 2019–2025

Across 214 payments — averaging $589.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$49K
  • SK Life Science, Inc.$31K
  • Livanova USA, Inc.$22K
  • Neurelis, Inc.$18K
  • Eisai Inc.$6K

What the payments were for

  • Consulting fees$18,09014%
  • Speaking & faculty fees$91,94973%
  • Travel & lodging$10,6368%
  • Food & beverage$5,5234%
  • Education$600%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Jazz Pharmaceuticals Inc.75$49,452
SK Life Science, Inc.49$30,550
Livanova USA, Inc.41$22,129
Neurelis, Inc.37$18,204
Eisai Inc.12$5,922

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$126,258 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$26,325
Medicare patients
193
Services billed
528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam194$312,111
XcopriCenobamate172$261,695
EpidiolexCannabidiol (Cbd)45$228,128
OnfiClobazam40$161,878
LamictalLamotrigine100$157,239
KeppraLevetiracetam43$130,002
VimpatLacosamide41$114,554
ZonegranZonisamide12$68,607
TopamaxTopiramate20$68,294
Rufinamide27$64,152
FycompaPerampanel40$58,833
Lamotrigine ErLamotrigine137$56,622
Lacosamide379$54,036
Clobazam341$51,000
AptiomEslicarbazepine Acetate12$34,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$30,550$261,695172 claims
Eisai Inc.Fycompa$5,922$58,83340 claims
Neurelis, Inc.Valtoco$18,204$34,33234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →